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Improved survival in acute leukaemia follows aggressive
combination chemotherapy based on a proper understand-
ing of tumour cell kinetics and principles of modern
pharmacology. Such cytoreduction regimens reduce tumour
mass to a level at which eradication by immune mechan-
isms becomes feasible, a fact presently being exploited
by immunotherapy programmes. Further improvement is
possible by the judicious use of sophisticated support
facilities such as laminar flow isolation areas and blood
fraction separators, but the cost and expertise of operating
such facilities limits availability to a few specialised
centres. Logically, patients with acute leukaemia should
have the benefit of management in these units.
S. Air. Med. l., 48, 1573 (1974).
Leukaemia may be divided into an acute form, where
rapid deterioration leads to death from haemorrhage or
infection in days or weeks, and a chronic type, in which
the relentless advance of this process may be very much
slower. These broad clinical patterns can be correlated
with the type of white cell present in the blood and the
bone marrow; in the former, primitive or blast cells
predominate, while greater degrees of leucocyte maturity
and differentiation are found in the latter. This classi-
fication may b~ extended to further subdivide the Ieukae-
m;as into either granuIocytic or lymphocytic varieties,
but such a distinction cannot always be made with
certainty. Nevertheless, the precise morphological diag-
nosis is worthy of special attention since it will influence
the choice of antileukaemic agents employed and so
become an important contribution to the long survival
being reported with increasing frequency in treated
patients.
The fact that significant prolongation of life is now
being achieved has necessitated a critical revision of th~
general philosophy attending the treatment of patients
with leukaemia. Tn the past, when the outlook for
survival was practically hopeless and when only a few
rather poor therapeutic agents were available, some
justification could perhaps be found for the use of
palliative therapy. Today, however, the employment of
more effective regimens has so improved the results of
treatment that a more aggressive approach, with curative
intent, is justified as the aim of therapy. Unfortunately,
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the complexity of the modern chemotherapeutic and
radio therapeutic schedules, esp~cially when superimposed
upon an already ill patient, require intensive care, meti-
culous isolaton and sophisticated haematalogical support.
Understandably, therefore, aggressive therapy is restricted
to those few hospitals willing to create and staff specially
equipped units.
The clear-cut improvement obtained in response to
treatment reflects, to a large extent, an increased awareness
of pharmacology and cell kinetics; both of these interact
to provide a logical basis for much of our present-day
drug scheduling. Tn addit'on to a better understanding of
these basic concepts, progress has also been made in
developing the necessary support programmes designed to
keep patients alive during intensive and myelosuppressive
chemotherapy. Since each of these advances has sub-
stantial implications for current therapy in patients with
leukaemia, further comment is warranted.
Concept of Cell Division
The most important aspect of pharmacology has per-
haps been the recognition of an interrelationship that
exists between drug action and cell division. During this
latter process a definite pattern of behaviour occurs, in
which mitosis is followed by a variable time in which
very little metabolic activity is evident-a period designated
Go or G,. The next period is occup:ed by DNA synthesis
-the S phase; a second rest period, or G" precedes further
cell division. This cell cycle plays a central role in
chemotherapy since certain drugs are maximally cytotoxic
during specific phases of division, and are designated
phase- or cycle-specific. By way of contrast, others inter-
fere with cell division non-specifically throughout the
cycle-the phase or cycle non-specific drugs. Manipulation
of drugs on the basis of this phenomenon can confer
some selectivity on the percentage kill achieved in any
given tumour depending upon its growth characteristics;
for example, phase-specific drugs are most effective during
times of rapid cell turnover, while phase non-specific drugs
have greater application in the treatment of large tumour
volumes with a low growth fraction.
Cellular Site of Activity of Drugs
In addition to these broad principles of action, the
cytotoxic drugs may also be grouped on the basis of their
specific sites of activity within the cell. Alkylating agents
produce damage during all phases of the cell cycle by
interstrand binding between N' in the guanine of one
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o 'A strand to the identical portion on the opposite
strand; antimetabolites are small molecules which resemble
the normal substrate in chemical structure, but differ
sufficiently to interfere with some vital chem:cal reaction
involving the metabolite-examples include methotrexate
and 6-mercaptopurine; the vinca alkaloids cause meta-
phase arrest by binding to the microtubular protein
necessary for mitotic formation; certain antibiotics, such
as daunorubicin, bind to D A and thus damage RNA
polymerase so that RNA synthesis is selectively blocked.
Clearly, familiarity with each aspect of drug action is
mandatory for doctors using these potentially dangerous
and sometimes lethal substances in the treatment of
patients.
Cell Kinetics
Turning now to cell kinetics, it is pertinent to emphasise
two aspects which have particular implication in the
treatment of leukaemia. Firstly, it is e~tablished that
normal and abnormal cells vary in their growth rate as
a function of tumour mass. Under physiological circum-
stances, as in the fetus, initial cell turnover is rapid, but
as development progresses and the mass increases, a
plateau is reached. A similar pattern is recognised in many
tumours. The phenomenon was characterised mathemati-
cally by Gompertz in the 18th century and is known as
Gompertzian growth. This particular relationship between
cell mass and growth rate has important application in
chemotherapy, since, in the periods when division is
rapid, tumours are vulnerable to cycle-specific drugs and
a high percentage kill can be achieved with these agents.
In contrast, cycle non-specific chemicals are more effective
in tumours having a large volume and a relatively slow
turnover.
A second aspect of cell kinetics that bears significantly
on treatment is the log cell-kill hypothesis which states
that a fixed percentage of cells are destroyed by a given
dose of drug. It is noteworthy that this cell-kill follows a
negative exponential function, making possible certain
predictions about therapy. Thus, it is estimated from
studies in humans and in experimental animals that
symptomatic acute leukaemia relates to a body burden of
I kg or about 10'" malignant cells. A 2 log cell-kill will
convert a marrow which is grossly leukaemic to one which
is morphologically normal, although the patient still
harbours 10'0 cells, and relapse is inevitable unless further
treatment is given. This observation can be integrated
with those referred to above, so that drug scheduling can
be arranged to achieve maximum tumour cell-kill while
a!lowing regeneration of the faster-growing normal tissue
to occur.
Immunotherapy
Clearly, chemotherapy alone would take a long time to
destroy all malignant cells and would also severely damage
normal tissue. The fact that very long survival has been
achieved when less than optimal chemotherapy is given.
implies the presence of some other defence mechanism
within the body. To accommodate this observation it has
been suggested that once a tumour mass has been reduced
from 10'" to about 10', the immune surveillance mechan-
ism may well be able to contain residual tumour and
perhaps even destroy these cells. Such a function for the
reticulo-endothelial system is exciting, and is now being
intensively examined with the object of developing
methods of enhancing any natural capacity that exists
for the eradication of foreign cells-an approach known
as immunotherapy.
Danger of Infections
In addition to harnessing pharmacology and cell kinetic
data in planning the treatment of patients with leukaemia.
a new dimension in management has been added by the
recent development of support programmes suitable for
maintaining life during periods of severely compromised
marrow function. Two aspects are especially noteworthy.
Firstly, individuals receiving intensive chemotherapy are
frequently severely immunosuppressed and at a risk from
a variety of infections. It has been shown that careful
isolation, combined with the judicious use of antibiotics,
may fde patients over this hazardous period. Technical
advances in the form of life-islands and laminar-flow
rooms, are further contributing to the successful outcome
of treatment by reducing the bacterial and viral content
of the air actually reaching the patients. Unfortunately,
the cost and expertise involved in providing these
facilities has, of necessity, restricted their availability to
medical schools and hospitals willing to accept the res-
ponsibility and make a special commitment for their
provision.
Secondly, it is well known that severe depression of
white cell and platelet levels occurs during the early
intensive phase of treatment, and it is logical that these
deficiencies should be corrected by the administration of
granulocyte-rich suspensions and platelet packs. The
routine use of the_e components, although tedious to
prepare, is often lifesaving. The introduction of blood-
fraction separators has greatly simplified the problem of
meeting these important requirements so that thrombo-
cytopenic bleeding and granulocyte-responsive bacterial
infections now pose a lesser problem. An additional
benefit accruing from the availability of these machines
is the ease with which an individual donor may
be re-used, just the particular fraction required being
removed and the remainder of the blood returned to the
donor. This technique has important therapeutic appli-
cation when repeated infusions with the possible produc-
tion of iso-antibodies is considered. Understandably,
careful white cell and tissue typing has assumed new
importance in patients where repeated but selected com-
ponents form an integral part of aggressive cytotoxic
chemotherapy.
IMPLICATIONS OF THESE ADVANCES
Treatment Centres
There is considerable literature to support the fact that
successful induction of complete remission in leukaemic
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patients, when followed by maintenance of a disease-free
state, is associated with a significantly prolonged survival.
Furthermore, the successful achievement of these objec-
tives is directly related to the proper selection and
effective administration of initial chemotherapy, two
decisions that largely depend upon thorough familiarity
with the drugs used and the availability of intensive
support· facilities for the patient. In view of the obvious
benefit and the unavoidable complexity of this modern
approach, the place of the 'occasional therapist' in
treating haematological malignancy must be seriously
questioned. There is increasing support for the suggestion
that all patients with leukaemia, Hodgkin's disease, and
other haematological malignancies be referred, immediately
upon diagnosis and before receiving any therapy, to
special units having appropriate facilities and expertise
for their detailed evaluation and over-all management.
Implicit in such a referral is the clear understanding that
close liaison will be maintained between primary physician
and staff of the special unit.
Acute ·Lymphoblastic Leukaemia
In focusing more specifically upon some of the benefits
that recent- therapeutic changes have effected in the
course of leukaemia, special mention should first be made
of acute lymphoblastic leukaemia, since it occurs predomi-
nantly in childhood. Relatively little difficulty is usually
experienced in achieving complete remission with a com-
bination of vincristine and prednisolone, although the
antitumour antibiotic, rubidomycin, may be added to the
regimen in those cases refractory to these two standard
induction drugs.
Two problems continue to plague the therapist dealing
with this form of leukaemia. Firstly, a number of these
children die from strange and exotic infections, frequently
caused by organisms which are normally commensals
The question is not yet resolved, and urgent study is
necessary to improve performance in this area, including
perhaps a critical analysis of the length of maintenance
treatment during the time when the patient is immuno-
suppressed.
Secondly, it is known that children enjoying good health
and having no evidence of leukaemia in the peripheral
blood or in the bone marrow, may relapse with overt
disease in the central nervous system. It was shown that
leukaemic cell rests or sanctuaries developed in this
anatomical site and were protected from the effects of
systematically administered agents. The problem has been
largely overcome by combining 2 400 rads of cranial
irradiation with intrathecal methotrexate. The addition
of craniospinal treatment has substantially improved the
outlook for these children so that longer disease- free
periods may be anticipated.
At the present time new avenues are being explored to
further prolong survival, and perhaps the most topical
of these is the question of immunotherapy. It is known
that neoplastic cells can be recognised by lymphocytes
of the immune surveillance mechanism and, under normal
circumstances, are destroyed. The basis for this recognition
is the fact that malignant cells carry on their membranes
new tumour-associated antigens, and it was predicted that
an immunological approach might therefore exist for the
treatment of leukaemia, especially when the number of
cells was not too great.
Initially, passive immunotherapy was employed ID
which serum containing cytotoxic antibodies directed
against tumour-specific antigens was administered, but
contamination with blocking antibodies has prevented
clinical evaluation. Adoptive immunotherapy was next
tried: here the thymus-dependent lymphocytes responsible
for cell-mediated immunity were used; difficulty has been
experienced in control of both engraftment and graft-
versus-host reaction. On the other hand, active immuno-
therapy, in which the patient's own immune reactions are
stimulated, have been extensively examined by Mathe and
his co-workers in Paris,' and these investigators present
some evidence for prolonged survival with this therapeutic
approach.
Acute Granulocytic Leukaemia
Turning to the question of acute granulocytic leukaemia,
the difficulties are most formidable. Induction of remission
and maintenance are both less easily achieved and are
each associated with a significant degree of bone marrow
depression. For this reason a greater finesse and experience
is needed in delivery of adequate amounts of the essenJial
therapy. At the present time a combination -of dauno-
rubicin and cytosine arabinoside are used for induction
of remission. Continuous cytosine arabinoside appears to
have advantages over the intermittent administration of
this drug, and early results suggest that induction may
be more easily achieved in the responsive patient with
this regimen.
The question of craniospinal treatment is less clearly
defined in acute granulocytic leukaemia, probably because
patient survival has been so short. However, a number
of individuals have clearly experienced meningeal relapse
at a time when blood and marrow are morphologically
disease-free; a situation analogous to that encountered in
acute lymphoblastic leukaemia. It is therefore logical that
as survival periods increase further, patients should be
protected from this complication by prophylactic radio-
therapy and intrathecal drugs. Our own practice has been
to deliver 3 500 rads to the cranium and instil cytosine
arabinoside into the cerebrospinal fluid.
The question of immunotherapy has received attention
in acute granulocytic leukaemia, largely from the group
at St Bartholomew's Hospital in London. Studies reported
by Dr Crowther and his colleagues' indicate that active
non-specific immunotherapy with irradiated lymphocytes
and BCG will prolong disease-free survival, and this
approach deserves further critical study.
The subvariety of acute granulocytic leukaemia,
.occurring late in the course of chronic granulocytic
leukaemia, is particularly difficult to treat, and it is
genera~ly considered that such blastic transformation is
refractory to therapy. We have recently had 3 con-
secutive patients enter remission after continuous intra-
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venous cytosine arabinoside and daunorubicin. The
numbers are small and statistically meaningless, but they
have stimulated us to examine our patients with chronic
granulocytic leukaemia more closely in an attempt to
identify this complication early and then use the more
aggressive chemotherapy.
Chronic Leukaemia
The whole question of chronic leukaemia is a confused
one and poses many therapeutic problems. It is likely that
part of the confusion results from the less rapid clinical
course and the unwillingness of doctors, therefore, to
administer potentially harmful therapy, at least in the
early stage of these diseases. However, it is important to
appreciate that nothing has prolonged median survival in
chronic granulocytic or chronic lymphocytic leukaemia,
a fact that is vitally important, since it should surely
stimulate us to review this policy and perhaps in:tiate
more aggressive but carefully selected treatment. This
latter qualification is important since some of these
patients are likely to enjoy a variable period of good
quality life before treatment becomes necessary, hence
the choice of therapy and its timing become matters of
fine judgement, in which a familiarity with the natural
history of these diseases is essential.
In chronic lymphocytic leukaemia, an asymptomatic
or benign form and an aggressive form are recognised
on clinical grounds. It is generally held that the former
does not require any therapy, but this philosophy should
not prevent careful study of the tumour so that information
can be obtained about its behaviour and the specific cell
type involved. Only in this way will some prediction be
possible as to which of these tumours are likely to alter
their course and become aggressive; presumably such
subtypes would justify earlier treatment.
The approach to the aggressive form of chronic lympho-
cytic leukaemia is more clear-cut. The development of
anaemia, thrombocytopenia, loss of weight and fever
constitute indications for treatment. In most of these
patients the choice of agents can be made after due
consideration of the bone marrow status. Chlorambucil
and prednisolone have long been the cornerstones of
therapy, although it should be recognised that this regimen
may aggravate thrombocytopenia at a time when the
marrow is densely infiltrated and residual haematopoiefc
cells are scanty. In this situation we have been most
impressed with the combination of vincristine and bleo-
mycin, given parenterally once a week for a month. Both
of these two agents are relatively non-myelotoxic and
vincristine may actually promote some degree of throm-
bocytosis via unknown mechanisms. Once substantial
depopulation of the marrow has been ach;eved, adminis-
tration of chlorambucil poses less of a problem.
Chronic granulocytic leukaemia is an equally distressing
problem in which median survival has also not changed
in the last decade, irrespective of the therapy used.
The British Medical Research Council trial indicated that
busulphan was preferable to radiotherapy, although details
of splenic irradiation were not given. Busulphan is
a potent drug with substantial toxicity, and for this
reason we have undertaken a re-evaluation of this moda-
lity of therapy in controlling the wmte cell count and
spleen size in patients with chronic granulocytic leukae-
mia. In 15 consecutive patients who received local radio-
therapy to the spleen, a gratifying response has been
documented in every patient. It is, however, too early to
know whether retreatment with radiotherapy will be
necessary and, if so, how frequently. Even less certain at
this stage is the question of whether this approach will
challenge the place of busulphan as the first modality of
treatment in these patients. Indeed, it is not yet clear
whether radiotherapy may not actually shorten the median
survival, as was suggested in the report from the British
Medical Research Council.
CONCLUSION
From these brief remarks it will be evident that, while
the salvage rate in leukaemia is still low, some progress
is being made in the treatment of acute leukaemia, mostly
in the area of acute lymphoblastic leukaemia in childhood.
By way of contrast a certain complacency has prevailed
with regard to the chronic leukaemias, possibly related
to their slower progression. Since no form of therapy has
significantly changed the median survival of patients with
either chronic granulocytic or chronic lymphocytic leu-
kaemia, a plea is made that these diseases should receive
additional study as a basis for developing new therapeutic
regimens and applying these at the appropriate time.
It may be concluded that chemotherapy for leukaemia
has advanced, but is yet in its infancy, employing methods
which are essentially non-selective. Nevertheless, the
rational use of cytotoxic agents has been given some basis
by studies of pharmacology and cell kinetics as a means of
determining the most appropriate forms of drug scheduling.
Significantly, further improvement in patient survival can
be attributed to the development of support facilities such
as laminar-fiow isolation rooms and blood-fraction
separators. On the other hand, the modest progress made
thus far should not in any way detract from further
studies aimed at elucidating aetiology, because only in this
way will specificity eventually be conferred upon our
therapeutic attempts.
Finally, the rapid changes that have occurred in the
treatment of haematological malignancy in the last decade
have necessitated the creation of special centres for the
total care of these patients. It is emphasised that the
therapy of these diseases is complex, and its optimal
delivery depends upon special knowledge of the chemo-
therapeutic regimens coupled with availability of well-
developed intensive nursing and support programmes.
Under these circumstances, there exists sound reason for
referring all such patients to centres offering special care
and expertise in their management.
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